Levamisole hydrochloride (C₁₁H₁₂N₂S·HCl; CAS 16595-80-5; relative molecular mass 240.75 g/mol) is a levorotatory imidazothiazole derivative supplied as a crystalline pharmaceutical-grade active pharmaceutical ingredient for oral solid and injectable manufacture. The product is released against the current Ph. Eur. and USP-NF monographs for Levamisole Hydrochloride; active-substance manufacture follows ICH Q7 GMP, with residual solvent control per ICH Q3C / USP ⟨467⟩ and elemental impurity control per ICH Q3D. Route-specific grades are designated by process suitability: LVH-PH-DC for direct compression, LVH-PH-WG for wet granulation, and LVH-PH-INJ for low-endotoxin injectable formulation. The direct-compression grade is milled to D90 ≤ 100 µm; the injectable grade is controlled for bacterial endotoxins at ≤ 0.50 EU/mg or tighter by dose derivation. Assay on the dried basis is 98.5–101.0%, total related substances ≤ 0.5%, loss on drying ≤ 0.5%, and sulfated ash ≤ 0.1%. The salt is freely soluble in water, enabling aqueous granulation, oral solution, and injectable processing without co-solvents.

Why does enantiomeric purity determine suitability for oral and injectable dosage forms?

Levamisole is the l-isomer of tetramisole; the racemic tetramisole base contains approximately equal proportions of the l- and d-enantiomers, while anthelmintic activity is associated predominantly with the l-form. Pharmacopoeial identity therefore includes specific optical rotation. Typical release material shows -119° to -127° (c=1, water, 20°C, Ph. Eur. 2.2.7). Compared with tetramisole hydrochloride, the enantiopure salt reduces the inactive d-enantiomer load and supports lower unit dosing. Compared with levamisole base, which is only sparingly soluble in water, the hydrochloride salt dissolves as a freely soluble species, making it technically suitable for aqueous parenterals and for solid oral work where disintegration should not be limited by API solubilization.

For tablet and capsule manufacture by wet granulation, the API is preblended with lactose monohydrate and maize starch in a high-shear granulator. Povidone K30 at 3–5% w/w of dry granulate is added as aqueous binder at impeller speed 250–350 rpm; wet mass is kneaded for 3–5 min, passed through a 1.0 mm screen, and dried in a fluid-bed dryer at inlet air 60–70°C to a final granule loss on drying of 1.5–2.5% w/w. Dried granulate is milled to a median granule size of 250–500 µm. Compression on a rotary tablet press at 8–20 kN main compression force yields tablets with hardness 50–100 N, friability ≤ 1.0% per USP ⟨1216⟩, and disintegration ≤ 15 min per USP ⟨701⟩ in purified water at 37±2°C. Capsule filling uses the same granulate lubricated with magnesium stearate at 0.5–1.0% w/w; over-lubrication above 2.0% w/w can delay dissolution because the water-soluble salt is sensitive to hydrophobic lubricant film coverage.

Which processing risk dominates direct compression at high API load?

Direct compression of levamisole hydrochloride at API loads above 60% w/w is constrained by powder flow rather than chemical stability. The unmilled crystalline powder can exhibit a Hausner ratio above 1.35, a condition associated with cohesive arching in feed hoppers and weight variation on high-speed rotary presses. The direct-compression grade is therefore dry milled to D90 ≤ 100 µm; however, excessive milling increases fines and can raise the Hausner ratio if the particle-size span is not controlled. Blending with spray-dried lactose and 0.5% w/w colloidal silicon dioxide typically reduces the Hausner ratio to 1.25–1.30 and the Carr index to 20–25%. On a rotary press operating at 60–80 rpm, 100 mg tablets containing 50 mg API show weight variation below 2% RSD. Punch filming has been observed when ambient relative humidity exceeds 60%; preconditioning the API at 40–50°C for 2 h and maintaining packaging-line humidity below 55% RH reduce sticking. This is a threshold zone because flow and sticking limits are narrower than the molecule’s chemical degradation limits.

For low-dose capsules at 25–50 mg API, the direct-compression grade is first diluted 1:5 to 1:10 with pregelatinized starch or microcrystalline cellulose before final blending. Content uniformity testing follows USP ⟨905⟩; for a 25 mg strength, an acceptance value ≤ 15 is applied. The blend is filled into hard gelatin or hypromellose capsules at a target fill weight of 100–200 mg using a dosator or tamping-pin encapsulation machine.

Injectable-grade levamisole hydrochloride is dissolved in Water for Injection at a concentration equivalent to 50–150 mg/mL of active base. The pH is adjusted to 3.5–4.5 with hydrochloric acid or sodium hydroxide; at this pH the molecule is protonated and aqueous oxidative discoloration is minimized. Osmolality is adjusted to 280–320 mOsm/kg with sodium chloride. Bulk solution is prefiltered through 0.45 µm and sterile-filtered through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane. Terminal sterilization at 121°C for 15 min is applied only if forced-degradation data demonstrate total related substances remain ≤ 0.5%; otherwise the standard is aseptic filtration followed by filling in an ISO 14644-1 Grade A zone. Bacterial endotoxins are governed by Ph. Eur. 5.1.10. A 150 mg dose for a 70 kg patient at 5 EU/kg permits 350 EU per container; an API release limit of 0.50 EU/mg contributes 75 EU, leaving margin for excipients and closure. Particulate matter testing follows USP ⟨788⟩ for small-volume injections: ≥ 10 µm particles ≤ 6000 per container and ≥ 25 µm particles ≤ 600 per container. Sterility testing follows USP ⟨71⟩ / Ph. Eur. 2.6.1.

If terminal sterilization is replaced by aseptic filtration, what validation parameters govern the process?

Where terminal sterilization is omitted, the sterile-filtration step is validated according to PDA Technical Report 26 and Ph. Eur. 5.1.1. The 0.22 µm filter is challenged with Brevundimonas diminuta ATCC 19146 at a load of ≥ 10⁷ CFU/cm²; filtrate is tested for sterility, and filter integrity is verified by bubble point or diffusion test before and after use. Bulk solution is held at 2–8°C for no longer than 24 h unless microbiological and stability data support longer. Pre-filtration bioburden is controlled to ≤ 10 CFU/100 mL before the sterilizing-grade filter. The mildly acidic pH of Levamisole Hydrochloride Injection aids bioburden control but does not substitute for aseptic processing.

For granule dosage forms, the drug substance is filled into sachets after wet or dry granulation. A typical sachet delivers 150 mg levamisole hydrochloride in a total granulate mass of 1.5–2.5 g. Dissolution testing uses USP apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid at 37±0.5°C; a commonly applied acceptance value is Q ≥ 80% at 30 min. Because the hydrochloride salt is freely soluble, dissolution is not normally rate-limiting; sachet uniformity is instead controlled by granule particle-size distribution and hopper flow. Granules with a median size of 250–500 µm and adequate porosity provide reproducible fill weights on auger fillers above 60 cycles/min. Taste-masking of oral granules, where required, is achieved by fluid-bed ethylcellulose coating at 3–5% w/w film weight gain; coating does not materially affect release in acid media if plasticizer content is controlled.

Pharmacopoeial Specification Matrix for Lot Release

The release attributes listed below distinguish pharmaceutical-grade material from unrefined or feed-grade sources.

Elemental impurities are controlled under ICH Q3D. For a parenteral route, the permitted daily exposures for Class 1 elements are 1.0 µg/day for arsenic, 0.15 µg/day for cadmium, 0.6 µg/day for lead, and 0.6 µg/day for mercury. Release data are generated by inductively coupled plasma mass spectrometry following USP ⟨233⟩ / Ph. Eur. 2.4.35. These route-specific elemental controls are absent from feed-grade material and are a primary difference for injectable use.

Comparative Differentiation from Tetramisole, Levamisole Base, and Feed-Grade Salts

The following matrix summarizes the material differences relevant to formulation and regulatory release.

Compared with pyrantel pamoate, which is practically insoluble in water, levamisole hydrochloride is freely soluble and can be formulated as an aqueous injection. Both act as nicotinic acetylcholine receptor agonists in nematodes, but levamisole is the enantiopure l-imidazothiazole and pyrantel is a tetrahydropyrimidine pamoate salt. Albendazole acts on β-tubulin and is poorly water-soluble, requiring suspension dosage forms. These differences place levamisole hydrochloride in oral solid and parenteral platform operations where dissolution is not the primary technical constraint.

Aqueous chemical stability is pH- and oxidation-dependent. Prolonged exposure to pH above 7.0 or to strong oxidizing agents such as hydrogen peroxide or permanganate increases related substances and should be avoided. The dry API is stored in tightly closed, light-resistant containers at controlled room temperature 15–25°C. For solid-dosage manufacturing, ambient relative humidity above 60% without preconditioning has been associated with picking and tablet weight variation on production rotary presses. Injectable compounding avoids contact with amine-reactive or oxidizing excipients. The material is transferred to the next unit operation only after the relevant pharmacopoeial release and route-specific endotoxin or particle-size requirements are met.